155 related articles for article (PubMed ID: 36848979)
1. Terlipressin Treatment Is Associated With Reversal of Hepatorenal Syndrome in Patients With Alcoholic Hepatitis.
Sigal SH; Sanyal AJ; Frederick RT; Weinberg EM; Pappas SC; Jamil K
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3455-3457.e3. PubMed ID: 36848979
[No Abstract] [Full Text] [Related]
2. Higher Respiratory Complications in Alcoholic Hepatitis Patients With Hepatorenal Syndrome When Treated With Terlipressin: Is it Safe?
Ariga KK; Verma G; Agrawal D
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3197-3198. PubMed ID: 37031717
[No Abstract] [Full Text] [Related]
3. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis.
Cervoni JP; Lecomte T; Cellier C; Auroux J; Simon C; Landi B; Gadano A; Barbier JP
Am J Gastroenterol; 1997 Nov; 92(11):2113-4. PubMed ID: 9362205
[TBL] [Abstract][Full Text] [Related]
4. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
[TBL] [Abstract][Full Text] [Related]
5. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
6. Terlipressin for hepatorenal syndrome.
Gluud LL; Christensen K; Christensen E; Krag A
Cochrane Database Syst Rev; 2012 Sep; (9):CD005162. PubMed ID: 22972083
[TBL] [Abstract][Full Text] [Related]
7. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.
Allegretti AS; Israelsen M; Krag A; Jovani M; Goldin AH; Schulman AR; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD005162. PubMed ID: 29943803
[TBL] [Abstract][Full Text] [Related]
8. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
Wang H; Liu A; Bo W; Feng X; Hu Y
Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
[TBL] [Abstract][Full Text] [Related]
9. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
Gifford FJ; Morling JR; Fallowfield JA
Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
[TBL] [Abstract][Full Text] [Related]
11. Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.
Allegretti AS; Subramanian RM; Francoz C; Olson JC; Cárdenas A
Liver Int; 2022 Oct; 42(10):2124-2130. PubMed ID: 35838488
[TBL] [Abstract][Full Text] [Related]
12. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients.
Dagher L; Patch D; Marley R; Moore K; Burroughs A
Aliment Pharmacol Ther; 2000 May; 14(5):515-21. PubMed ID: 10792112
[TBL] [Abstract][Full Text] [Related]
13. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis: terlipressin therapy for the hepatorenal syndrome.
Fabrizi F; Dixit V; Martin P
Aliment Pharmacol Ther; 2006 Sep; 24(6):935-44. PubMed ID: 16948805
[TBL] [Abstract][Full Text] [Related]
15. Board Review Vignette: Lessons Learned in the Management of Hepatorenal Syndrome Type 1 With Terlipressin.
Gonzalez SA; Velez JCQ
Am J Gastroenterol; 2022 Apr; 117(4):520-523. PubMed ID: 35029160
[No Abstract] [Full Text] [Related]
16. Letter: real-world use of terlipressin in patients with hepatorenal syndrome.
Weng F
Aliment Pharmacol Ther; 2021 Aug; 54(3):349. PubMed ID: 34236098
[No Abstract] [Full Text] [Related]
17. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
18. Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
Kalambokis GN; Baltayiannis G; Christodoulou D; Christou L
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1428-1429. PubMed ID: 29111999
[No Abstract] [Full Text] [Related]
19. Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature.
Kalil JR; Cerqueira LA; Barbosa DS; Motta MP; Nery Mda S; Bittencourt PL
Arq Gastroenterol; 2009; 46(3):214-8. PubMed ID: 19918689
[TBL] [Abstract][Full Text] [Related]
20. Letter: real-world use of terlipressin in patients with the hepatorenal syndrome-authors' reply.
Allegretti AS; Jamil K; Moore K
Aliment Pharmacol Ther; 2021 Aug; 54(3):350-351. PubMed ID: 34236097
[No Abstract] [Full Text] [Related]
[Next] [New Search]
